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A 56-year-old woman in Helena, Montana, USA, who 
showed  clinical  signs  of  paralysis,  received  antitoxins  to 
botulinum toxins A, B, and E within 24 hours; nevertheless, 
symptoms progressed to complete quadriplegia. On day 8, 
she began moving spontaneously, even though blood tests 
later showed botulinum toxin type F remained. 
B
otulism is a disease characterized by cranial nerve 
palsies and descending, symmetric, flaccid paralysis. 
Seven serologically distinct botulinum toxins, designated 
A through G, are known; virtually all human cases are 
caused by types A, B, E, and rarely, F (1). Clostridium 
botulinum produces all 7 toxin types (2–4). Toxin type E 
may also be produced by C. butyricum (5), and type F by 
C. baratii (6–9). 
Botulism type F causes ≈1% of botulism cases in the 
United States (10). Two outbreaks have been reported, 1 in 
the United States, the other in Europe (4,11,12). A recent 
review described all 13 cases of botulism type F from the 
USA between 1981 and 2002 (9). Clinical signs were respi-
ratory failure within 24 hours of symptom onset, complete 
or near complete quadriplegia by the fifth day, and neuro-
muscular recovery beginning on the eighth day. On aver-
age, patients received mechanical ventilation for 24 days 
and were hospitalized for 30 days. These features represent 
a more precipitous initial course than is typical for type A 
or type B botulism but a more rapid recovery. We describe 
a case of botulism type F in an adult who recovered despite 
the continued presence of toxin in the blood.
The Case
In 2005, a 56-year-old woman sought treatment at the 
emergency department of a hospital in Helena, Montana, 
USA. She reported right-upper quadrant pain radiating to 
her back of 1 day’s duration and shortness of breath. Her 
medical  history  included  hypertension,  hyperlipidemia, 
and gastroesophageal reflux. The abdomen was tender at 
the right upper quadrant. Routine blood test results were 
unremarkable; an abdominal radiograph showed copious 
stool and gas. The patient had respiratory arrest in the emer-
gency department and was intubated. She had unresponsive 
pupils dilated to 5 mm, minimal extraoccular muscle mo-
tion, facial paralysis, normal palatal and gag reflexes, near-
paralysis of proximal upper and lower extremities but near 
normal muscle strength in the hands and feet, and symmet-
ric deep tendon reflexes. Results of computed tomographic 
scans of the brain, chest, and abdomen were unremarkable. 
Cerebrospinal fluid values were within normal limits. An 
electromyogram  (EMG)  showed  normal  sensory  nerve 
function, low amplitude on motor stimulation, mild (10%) 
decremental response on repetitive low frequency, and in-
cremental response on high-frequency nerve stimulation, 
consistent with botulism (13).
Antitoxins to botulinum toxin types A, B, and E were 
administered within 24 hours. Nevertheless, paralysis pro-
gressed after antitoxin administration; within 48 hours, the 
patient was quadriplegic with no voluntary muscle func-
tion or distal tendon reflexes. On hospitalization day 4, a 
repeat EMG study showed no response to repetitive nerve 
stimulation.
The first improvement in neurologic status occurred 
on hospitalization day 8, when she moved her eyebrows, 
shook her head horizontally and laterally, lightly gripped, 
and plantarflexed and dorsiflexed her feet. Heart rate, which 
had been notably fixed at ≈70 beats/min, began varying for 
the first time. The Centers for Disease Control and Pre-
vention (CDC; Atlanta, GA, USA) provided heptavalent 
(anti-ABCDEFG)  equine  F(ab′)2  antitoxin,  but  because 
of progressive clinical improvement, it was surmised that 
no toxin remained in circulation, and the antitoxin was not 
administered. Her neurologic function gradually improved; 
cranial nerve function was substantially improved by hos-
pitalization day 12, although the pupils remained fixed for 
much longer. The first bowel movement, with enema, oc-
curred on day 13. Distal tendon reflexes were first noted on 
day 17. On day 25, the patient combed her own hair. Wean-
ing from mechanical ventilation was completed on day 35.
The patient underwent 1 week of in-hospital physi-
cal therapy, 3 hours per day. This period was marked by 
intermittent lightheadedness, orthostatic hypotension, and 
fatigue. Complications during hospitalization were aspira-
tion pneumonia, Candida glabrata urinary tract infection 
with fungemia, heart failure attributed to diastolic dysfunc-
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tion on day 47. After hospitalization the patient reported 
that she required help getting out of bed and bathing for 
1 month, help dressing for 2 months, and help getting up 
from a seated position for >7 months. She reported attain-
ing pre-illness health 10 months after discharge.
Botulinum toxin type F was identified by mouse bio-
assay (2) at the Utah Public Health Laboratories in serum 
samples drawn on hospital days 1 and 8. Testing was con-
firmed at CDC. Test results were reported 21 days after 
serum collection, by which time treatment with specific 
antitoxin was not deemed necessary in view of substantial 
neurologic improvement. No protection was conferred on 
mice by antitoxins to botulinum toxins A, B, or E. A stool 
sample collected on hospital day 1 tested negative for botu-
linum toxin but yielded C. baratii that produced botulinum 
toxin type F. Public health officials did not identify any 
suspect food or other potential source of exposure.
Conclusions
The clinical characteristics of this case closely resem-
ble those in previously described adult botulism F patients 
(9). Our patient experienced respiratory collapse before her 
neurologic deficits were known, progressed to complete 
quadriplegia within 2 days, and showed the first signs of 
neurologic recovery on day 8. She was respirator depen-
dent for 35 days and hospitalized for 45 days.
The  patient  had  documented  circulating  botulinum 
toxin type F on hospital days 1 and 8. The assay’s limit 
of detection is ≈1 50% mouse intraperitoneal lethal dose   
(MIPLD50) per milliliter of patient blood. Therefore, esti-
mating the patient’s circulatory volume at 5,000 mL whole 
blood and 3,000 mL plasma, this patient had a minimum of 
3,000 MIPLD50 of type F toxin in circulation (apart from 
intracellular and bound toxin) on day 8 of hospitalization, 
the same day she demonstrated the first unequivocal signs 
of recovery from total quadriplegia. The type F toxin sub-
cutaneous lethal dose in rhesus monkeys has been estimat-
ed at 25 MIPLD50/kg and the oral lethal dose at >4 × 106 
MIPLD50/kg (3). We cannot explain the patient’s clinical 
improvement in the face of circulating active toxin.
We were unable to determine whether the patient had 
foodborne or adult colonization botulism. Gupta et al. re-
ported that, of 13 adult type F cases, 2 had confirmed adult 
colonization and 1 may have had foodborne botulism, but 
the syndrome in the remaining patients was not known (9). 
Infant type F botulism, by definition a colonization condi-
tion, does occur (14,15).
The economic burden of illness in this case was sub-
stantial. Apart from hospital charges of US $230,000, the 
patient required constant care by a relative and could not 
work for at least 7 months.
The similarity of the clinical features of this case with 
those previously described (8) indicate a highly predictable 
course of illness for botulism type F intoxication. Early 
suspicion of type F intoxication, suggested by specimens 
producing positive mouse assay results without protection 
of mice by injection of antitoxins for botulism toxins A, 
B, or E, may facilitate timely treatment with experimental 
type-specific antitoxin, available from CDC. Stool samples 
should be cultured over an extended period to assess for 
possible intestinal colonization.
We describe circulation of botulinum toxin in a patient 
on the day she demonstrated the first signs of recovery from 
complete quadriplegia. When future type F cases are identi-
fied by the presence of type F toxin in clinical specimens, 
the patient should be promptly treated with the appropri-
ate antitoxin. The possibility of type F illness should be 
suspected if onset is rapid and paralysis is severe, and the 
laboratory should conduct immediate, specific testing. In-
tensive care support and antitoxin treatment are the stan-
dards for botulism care (2). Suspected cases of botulism of 
any type should be immediately reported to the state health 
department’s 24-hour emergency telephone number. 
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